<DOC>
	<DOCNO>NCT00831857</DOCNO>
	<brief_summary>The primary objective study evaluate feasibility 89Zr-bevacizumab PET image biomarker treatment sunitinib bevacizumab plus interferon patient RCC . 89Zr-bevacizumab PET imaging regard promising biomarker target treatment ( VEGF ) visualise uptake change institution treatment .</brief_summary>
	<brief_title>VEGF Imaging Renal Cell Carcinoma</brief_title>
	<detailed_description>- To explore 89Zr-bevacizumab PET image differentiate RCC patient progressive disease patient non-progressive disease treatment sunitinib bevacizumab plus interferon . - To explore relationship VEGF pathway related biomarkers 89Zr-bevacizumab PET response . - To explore effect 2 week treatment sunitinib arm pharmacodynamic biomarkers 89Zr-bevacizumab PET response .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Inclusion criterion : locally advance irresectable metastatic renal cell cancer untreated brain metastasis ( CT MRI necessary absence symptom ) uncontrolled hypertension clinically significant cardiovascular event disease last 12 month surgery last 4 week treatment bevacizumab another monoclonal antibody antiangiogenic property last 4 month treatment tyrosine kinase inhibitor last 4 week measurable disease xray CT scan , least one site disease must unidimensionally measurable follow : Xray &gt; 20 mm , Spiral CT scan &gt; 10 mm , nonspiral CT scan &gt; 20 mm clear cell histology component pregnant nursing woman childbearing potential must use effective contraception absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial patient randomization , write informed consent must give accord GCP , local regulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>